The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies

  1. Jennifer EL Diaz
  2. Mehmet Eren Ahsen
  3. Thomas Schaffter
  4. Xintong Chen
  5. Ronald B Realubit
  6. Charles Karan
  7. Andrea Califano
  8. Bojan Losic
  9. Gustavo Stolovitzky  Is a corresponding author
  1. Icahn School of Medicine at Mount Sinai, United States
  2. IBM Research, United States
  3. Columbia University, United States

Abstract

Our ability to discover effective drug combinations is limited, in part by insufficient understanding of how the transcriptional response of two monotherapies results in that of their combination. We analyzed matched time course RNAseq profiling of cells treated with single drugs and their combinations and found that the transcriptional signature of the synergistic combination was unique relative to that of either constituent monotherapy. The sequential activation of transcription factors in time in the gene regulatory network was implicated. The nature of this transcriptional cascade suggests that drug synergy may ensue when the transcriptional responses elicited by two unrelated individual drugs are correlated. We used these results as the basis of a simple prediction algorithm attaining an AUROC of 0.77 in the prediction of synergistic drug combinations in an independent dataset.

Data availability

Raw RNAseq data have been deposited in GEO under accession code GSE149428. Code is available at github.com/jennifereldiaz/drug-synergy.

The following previously published data sets were used

Article and author information

Author details

  1. Jennifer EL Diaz

    Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    No competing interests declared.
  2. Mehmet Eren Ahsen

    Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    No competing interests declared.
  3. Thomas Schaffter

    IBM Computational Biology Center, IBM Research, Yorktown Heights, United States
    Competing interests
    No competing interests declared.
  4. Xintong Chen

    Department of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    No competing interests declared.
  5. Ronald B Realubit

    Department of Systems Biology, Sulzberger Columbia Genome Center, High Throughput Screening Facility, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  6. Charles Karan

    Department of Systems Biology, Sulzberger Columbia Genome Center, High Throughput Screening Facility, Columbia University, New York, United States
    Competing interests
    No competing interests declared.
  7. Andrea Califano

    Department of Systems Biology, Department of Biomedical Informatics, Department of Biochemistry and Molecular Biophysics, J.P. Sulzberger Columbia Genome Center, Herbert Irving Comprehensive Cancer, Columbia University, New York, United States
    Competing interests
    Andrea Califano, Dr. Califano is founder, equity holder, consultant, and director of DarwinHealth Inc., a company that has licensed some of the algorithms used in this manuscript from Columbia University. Columbia University is also an equity holder in DarwinHealth Inc..
  8. Bojan Losic

    Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3643-4612
  9. Gustavo Stolovitzky

    IBM Computational Biology Center, IBM Research, Yorktown Heights, United States
    For correspondence
    gustavo@us.ibm.com
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9618-2819

Funding

Internal funding from IBM Research and the Icahn School of Medicine at Mount Sinai to GS

  • Jennifer EL Diaz
  • Mehmet Eren Ahsen
  • Thomas Schaffter
  • Xintong Chen
  • Bojan Losic
  • Gustavo Stolovitzky

National Institutes of Health (NIH T32 GM007280)

  • Jennifer EL Diaz

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Alfonso Valencia, Barcelona Supercomputing Center - BSC, Spain

Version history

  1. Received: October 13, 2019
  2. Accepted: August 17, 2020
  3. Accepted Manuscript published: September 18, 2020 (version 1)
  4. Version of Record published: October 9, 2020 (version 2)

Copyright

© 2020, Diaz et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 7,639
    views
  • 776
    downloads
  • 19
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jennifer EL Diaz
  2. Mehmet Eren Ahsen
  3. Thomas Schaffter
  4. Xintong Chen
  5. Ronald B Realubit
  6. Charles Karan
  7. Andrea Califano
  8. Bojan Losic
  9. Gustavo Stolovitzky
(2020)
The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies
eLife 9:e52707.
https://doi.org/10.7554/eLife.52707

Share this article

https://doi.org/10.7554/eLife.52707

Further reading

    1. Cell Biology
    Ang Li, Jianxun Yi ... Jingsong Zhou
    Research Article

    Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disorder characterized by progressive weakness of almost all skeletal muscles, whereas extraocular muscles (EOMs) are comparatively spared. While hindlimb and diaphragm muscles of end-stage SOD1G93A (G93A) mice (a familial ALS mouse model) exhibit severe denervation and depletion of Pax7+satellite cells (SCs), we found that the pool of SCs and the integrity of neuromuscular junctions (NMJs) are maintained in EOMs. In cell sorting profiles, SCs derived from hindlimb and diaphragm muscles of G93A mice exhibit denervation-related activation, whereas SCs from EOMs of G93A mice display spontaneous (non-denervation-related) activation, similar to SCs from wild-type mice. Specifically, cultured EOM SCs contain more abundant transcripts of axon guidance molecules, including Cxcl12, along with more sustainable renewability than the diaphragm and hindlimb counterparts under differentiation pressure. In neuromuscular co-culture assays, AAV-delivery of Cxcl12 to G93A-hindlimb SC-derived myotubes enhances motor neuron axon extension and innervation, recapitulating the innervation capacity of EOM SC-derived myotubes. G93A mice fed with sodium butyrate (NaBu) supplementation exhibited less NMJ loss in hindlimb and diaphragm muscles. Additionally, SCs derived from G93A hindlimb and diaphragm muscles displayed elevated expression of Cxcl12 and improved renewability following NaBu treatment in vitro. Thus, the NaBu-induced transcriptomic changes resembling the patterns of EOM SCs may contribute to the beneficial effects observed in G93A mice. More broadly, the distinct transcriptomic profile of EOM SCs may offer novel therapeutic targets to slow progressive neuromuscular functional decay in ALS and provide possible ‘response biomarkers’ in pre-clinical and clinical studies.

    1. Cell Biology
    Simona Bolamperti, Hiroaki Saito ... Hanna Taipaleenmäki
    Research Article

    Osteoblast adherence to bone surfaces is important for remodeling bone tissue. This study demonstrates that deficiency of TG-interacting factor 1 (Tgif1) in osteoblasts results in altered cell morphology, reduced adherence to collagen type I-coated surfaces, and impaired migration capacity. Tgif1 is essential for osteoblasts to adapt a regular cell morphology and to efficiently adhere and migrate on collagen type I-rich matrices in vitro. Furthermore, Tgif1 acts as a transcriptional repressor of p21-activated kinase 3 (Pak3), an important regulator of focal adhesion formation and osteoblast spreading. Absence of Tgif1 leads to increased Pak3 expression, which impairs osteoblast spreading. Additionally, Tgif1 is implicated in osteoblast recruitment and activation of bone surfaces in the context of bone regeneration and in response to parathyroid hormone 1–34 (PTH 1–34) treatment in vivo in mice. These findings provide important novel insights in the regulation of the cytoskeletal architecture of osteoblasts.